FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials
Executive Summary
Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain
You may also be interested in...
Esbriet, Ofev Reviews Convinced FDA Of Acceptable IPF Endpoint
FDA leaders explain in NEJM how they came to accept a measure of lung function as a surrogate for mortality in trials of idiopathic pulmonary fibrosis therapies. See how agency reviewers handled this in a preview of our upcoming Drug Review Profile series.
Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis
The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.
Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis
The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.